| 产品名称： | HL-60/MX2 |
|---|---|
| 商品货号： | TS211999 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute promyelocytic leukemia |
| Age： | 36 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Karyotype： | The cells exhibit a reciprocal translocation rcpt(1;3)-(q21;p23) not found in the parental cell line. |
| Derivation： | HL-60/MX2 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia. HL-60/MX1 (see ATCC CRL-2258) cells were selected and subcloned in 1987 for resistance to 39 nM mitoxantrone, an anthracenedione antitumor agent. Subsequent exposure of the HL-60/MX1 cells to higher concentrations of mitoxantrone led to the emergence of cells capable of growth at a concentration of 190 nM. These cells were cloned by limiting dilution in soft agar, propagated and tested for sensitively to mitoxantrone. |
| Clinical Data： | 36 years
Caucasian
female
|
| Comments： | The clone designated HL-60/MX2 was approximately 35 fold less sensitive to mitoxantrone than the HL-60 parental cells. HL-60/MX2 cells display atypical multidrug resistance (MDR) with the absence of P-glycoprotein overexpression and altered topoisomerase II catalytic activity and reduced levels of topoisomerase II alpha and beta proteins. HL-60/MX2 cells are cross-resistant to etoposide, teniposide, bisantrene, dactinomycin, 4-(9-acridinylamino)methane- sulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids vincristine and vinblastine, melphalan, mitomycin C and cisplatin. The HL-60/MX2 cells display slight collateral sensitivity to bleomycin.
Resistance to mitoxantrone is stable for up to six months.
|
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1xa0- 2xa0x 105 viable cells/mL. Maintain cultures at a cell concentration between 2 x 105 and 1.5 x 106 cells/mL. Never allow the cell concentration to exceed 2 x 106 cells/mL. Interval: Maintain cell density between 1xa0x 105 and 1.5xa0x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 13,14 D13S317: 8,11 D16S539: 11 D5S818: 12 D7S820: 11,12 THO1: 7,8 TPOX: 8,11 vWA: 16 |
| Population Doubling Time： | 30 hrs |
| Name of Depositor： | WG Harker |
| Deposited As： | Homo sapiens |
| References： | Harker WG, et al. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49: 4542-4549, 1989. PubMed: 2568172 Harker WG, et al. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30: 9953-9961, 1991. PubMed: 1655025 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | HL-60/MX2 |
|---|---|
| 商品货号： | TS211999 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute promyelocytic leukemia |
| Age： | 36 years |
| Gender： | female |
| Ethnicity： | Caucasian |
| Storage Conditions： | liquid nitrogen vapor phase |
| Karyotype： | The cells exhibit a reciprocal translocation rcpt(1;3)-(q21;p23) not found in the parental cell line. |
| Derivation： | HL-60/MX2 is a mitoxantrone resistant derivative of the HL-60 cell line (see ATCC CCL-240) which was obtained from peripheral blood leukocytes obtained by leukopheresis from patient with acute promyelocytic leukemia. HL-60/MX1 (see ATCC CRL-2258) cells were selected and subcloned in 1987 for resistance to 39 nM mitoxantrone, an anthracenedione antitumor agent. Subsequent exposure of the HL-60/MX1 cells to higher concentrations of mitoxantrone led to the emergence of cells capable of growth at a concentration of 190 nM. These cells were cloned by limiting dilution in soft agar, propagated and tested for sensitively to mitoxantrone. |
| Clinical Data： | 36 years
Caucasian
female
|
| Comments： | The clone designated HL-60/MX2 was approximately 35 fold less sensitive to mitoxantrone than the HL-60 parental cells. HL-60/MX2 cells display atypical multidrug resistance (MDR) with the absence of P-glycoprotein overexpression and altered topoisomerase II catalytic activity and reduced levels of topoisomerase II alpha and beta proteins. HL-60/MX2 cells are cross-resistant to etoposide, teniposide, bisantrene, dactinomycin, 4-(9-acridinylamino)methane- sulfon-m-anisidide, and the anthracyclines daunorubicin and doxorubicin but retain sensitivity to the Vinca alkaloids vincristine and vinblastine, melphalan, mitomycin C and cisplatin. The HL-60/MX2 cells display slight collateral sensitivity to bleomycin.
Resistance to mitoxantrone is stable for up to six months.
|
| Complete Growth Medium： | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing： | Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1xa0- 2xa0x 105 viable cells/mL. Maintain cultures at a cell concentration between 2 x 105 and 1.5 x 106 cells/mL. Never allow the cell concentration to exceed 2 x 106 cells/mL. Interval: Maintain cell density between 1xa0x 105 and 1.5xa0x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 13,14 D13S317: 8,11 D16S539: 11 D5S818: 12 D7S820: 11,12 THO1: 7,8 TPOX: 8,11 vWA: 16 |
| Population Doubling Time： | 30 hrs |
| Name of Depositor： | WG Harker |
| Deposited As： | Homo sapiens |
| References： | Harker WG, et al. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 49: 4542-4549, 1989. PubMed: 2568172 Harker WG, et al. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30: 9953-9961, 1991. PubMed: 1655025 |
